These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 19223285)

  • 1. Anti-TNF-alpha therapy for rheumatoid arthritis among patients with chronic hepatitis B infection.
    Robinson H; Walker-Bone K
    Rheumatology (Oxford); 2009 Apr; 48(4):448-50. PubMed ID: 19223285
    [No Abstract]   [Full Text] [Related]  

  • 2. Use of tumor necrosis factor-alpha inhibitors in patients with chronic hepatitis B infection.
    Carroll MB; Bond MI
    Semin Arthritis Rheum; 2008 Dec; 38(3):208-17. PubMed ID: 18221983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of anti-TNF-alpha therapy in rheumatoid arthritis and spondylarthropathies with concurrent B or C chronic hepatitis.
    Roux CH; Brocq O; Breuil V; Albert C; Euller-Ziegler L
    Rheumatology (Oxford); 2006 Oct; 45(10):1294-7. PubMed ID: 16603583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy.
    Lan JL; Chen YM; Hsieh TY; Chen YH; Hsieh CW; Chen DY; Yang SS
    Ann Rheum Dis; 2011 Oct; 70(10):1719-25. PubMed ID: 21719446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of infliximab in a patient with rheumatoid arthritis and chronic hepatitis B.
    Doubrawa E; Ricca RA; Malucelli TO; Pizzol VI; Barros DH; Paiva ES
    Rev Bras Reumatol; 2012 Aug; 52(4):653-5. PubMed ID: 22885430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection.
    Vassilopoulos D; Apostolopoulou A; Hadziyannis E; Papatheodoridis GV; Manolakopoulos S; Koskinas J; Manesis EK; Archimandritis AI
    Ann Rheum Dis; 2010 Jul; 69(7):1352-5. PubMed ID: 20472596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumour necrosis factor-α antagonists in patients with concurrent psoriasis and hepatitis B or hepatitis C: a retrospective analysis of 17 patients.
    Prignano F; Ricceri F; Pescitelli L; Zanieri F; Lotti T
    Br J Dermatol; 2011 Mar; 164(3):645-7. PubMed ID: 21375517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adalimumab-induced lethal hepatitis B virus reactivation in an HBsAg-negative patient with clinically resolved hepatitis B virus infection.
    Matsumoto T; Marusawa H; Dogaki M; Suginoshita Y; Inokuma T
    Liver Int; 2010 Sep; 30(8):1241-2. PubMed ID: 20345703
    [No Abstract]   [Full Text] [Related]  

  • 9. Use of anti-tumor necrosis factor-α therapy in hepatitis B virus carriers with psoriasis or psoriatic arthritis: a case series in Taiwan.
    Cho YT; Chen CH; Chiu HY; Tsai TF
    J Dermatol; 2012 Mar; 39(3):269-73. PubMed ID: 22077677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic viral hepatitis and TNF-alpha blockade.
    Raftery G; Griffiths B; Kay L; Kane D
    Rheumatology (Oxford); 2007 Aug; 46(8):1381; author reply 1381-2. PubMed ID: 17567635
    [No Abstract]   [Full Text] [Related]  

  • 11. B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents.
    Finckh A; Ciurea A; Brulhart L; Kyburz D; Möller B; Dehler S; Revaz S; Dudler J; Gabay C;
    Arthritis Rheum; 2007 May; 56(5):1417-23. PubMed ID: 17469098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improvement of renal function and disappearance of hepatitis B virus DNA in a patient with rheumatoid arthritis and renal amyloidosis following treatment with infliximab.
    Anelli MG; Torres DD; Manno C; Scioscia C; Iannone F; Covelli M; Schena FP; Lapadula G
    Arthritis Rheum; 2005 Aug; 52(8):2519-20. PubMed ID: 16052569
    [No Abstract]   [Full Text] [Related]  

  • 13. [Correlation between different clinical activity and anti CC-P (anti-cyclic citrullinated peptide antibodies) titres in rheumatoid arthritis treated with three different tumor necrosis factors TNF-alpha blockers].
    Benucci M; Turchini S; Parrochi P; Boccaccini P; Manetti R; Cammelli E; Manfredi M
    Recenti Prog Med; 2006 Mar; 97(3):134-9. PubMed ID: 16700418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Graves' disease in a patient with rheumatoid arthritis during treatment with anti-tumor necrosis factor-alpha.
    van Lieshout AW; Creemers MC; Radstake TR; Elving LD; van Riel PL
    J Rheumatol; 2008 May; 35(5):938-9. PubMed ID: 18464319
    [No Abstract]   [Full Text] [Related]  

  • 15. Anti-tumor necrosis factor agents for rheumatoid arthritis in the setting of chronic hepatitis C infection.
    Parke FA; Reveille JD
    Arthritis Rheum; 2004 Oct; 51(5):800-4. PubMed ID: 15478165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital.
    Suwannalai P; Auethavekiat P; Udomsubpayakul U; Janvitayanujit S
    Int J Rheum Dis; 2009 Jul; 12(2):118-24. PubMed ID: 20374328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short-term course of chronic hepatitis B and C under treatment with etanercept associated with different disease modifying antirheumatic drugs without antiviral prophylaxis.
    Cansu DU; Kalifoglu T; Korkmaz C
    J Rheumatol; 2008 Mar; 35(3):421-4. PubMed ID: 18203328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reactivation of hepatitis B viral infection in inactive HBsAg carriers following anti-tumor necrosis factor-alpha therapy.
    Chung SJ; Kim JK; Park MC; Park YB; Lee SK
    J Rheumatol; 2009 Nov; 36(11):2416-20. PubMed ID: 19797507
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment?
    Askling J; van Vollenhoven RF; Granath F; Raaschou P; Fored CM; Baecklund E; Dackhammar C; Feltelius N; Cöster L; Geborek P; Jacobsson LT; Lindblad S; Rantapää-Dahlqvist S; Saxne T; Klareskog L
    Arthritis Rheum; 2009 Nov; 60(11):3180-9. PubMed ID: 19877027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. No change of serum levels of leptin and adiponectin during anti-tumour necrosis factor antibody treatment with adalimumab in patients with rheumatoid arthritis.
    Härle P; Sarzi-Puttini P; Cutolo M; Straub RH
    Ann Rheum Dis; 2006 Jul; 65(7):970-1. PubMed ID: 16769786
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.